scholarly journals Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy

Diabetes Care ◽  
2019 ◽  
Vol 42 (4) ◽  
pp. 585-593 ◽  
Author(s):  
Erin S. Morgan ◽  
Li-Jung Tai ◽  
Nguyen C. Pham ◽  
Julia K. Overman ◽  
Lynnetta M. Watts ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycogen Content ◽  
Hepatic Glycogen ◽  
Antisense Inhibition ◽  
Glucagon Receptor ◽  
Metformin Therapy

227-OR: The Effect of Dietary Fiber in Combination with Metformin Therapy in Type 2 Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 227-OR
Author(s):  
FLAVIA TRAMONTANA ◽  
ERNESTO MADDALONI ◽  
SARA GRECI ◽  
GIUSEPPE DEFEUDIS ◽  
ROCKY STROLLO ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dietary Fiber ◽  
Metformin Therapy

Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes

2013 ◽  
Vol 13 (3) ◽  
pp. 256-263 ◽  
Author(s):  
Ilker Tasci ◽  
Mehmet Naharci ◽  
Ergun Bozoglu ◽  
Umut Safer ◽  
Aydogan Aydogdu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Metformin Therapy

Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential

Physiology ◽  
2005 ◽  
Vol 20 (5) ◽  
pp. 357-365 ◽  
Author(s):  
Elaine M Sinclair ◽  
Daniel J. Drucker
Keyword(s):  
Type 2 Diabetes ◽  
Human Disease ◽  
Clinical Relevance ◽  
Therapeutic Potential ◽  
Mechanisms Of Action ◽  
Receptor Antagonists ◽  
Glucagon Receptor ◽  
Receptor Agonists ◽  
Glucagon Like Peptide

Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic actions of the proglucagon-derived peptides, with an emphasis on clinical relevance of the peptides for the treatment of human disease.

scholarly journals Treatment strategy of type 2 diabetes used in Czech Republic after metformin therapy failure

2017 ◽  
Vol 63 (10) ◽  
pp. 647-657
Author(s):  
Štěpán Svačina ◽  
Petra Ovesná ◽  
Matyáš Kuhn ◽  
Martina Nováčková
Keyword(s):  
Type 2 Diabetes ◽  
Czech Republic ◽  
Treatment Strategy ◽  
Therapy Failure ◽  
Metformin Therapy

scholarly journals Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults with Overweight or Obesity and Type 2 Diabetes Mellitus: A 54-Week Randomized Phase 2b Study

2021 ◽  
Author(s):  
Rajaa Nahra ◽  
Tao Wang ◽  
Kishore M. Gadde ◽  
Jan Oscarsson ◽  
Michael Stumvoll ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Body Weight ◽  
Ad Hoc ◽  
Open Label ◽  
Double Blind ◽  
Glucagon Receptor ◽  
Nonalcoholic Fatty Liver ◽  
Design And Methods

<a><b>Objective: </b></a>Cotadutide, a <a>dual GLP-1 and glucagon receptor agonist</a>, is under development for nonalcoholic steatohepatitis (NASH) and type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes. <p><b>Research Design and Methods:</b> In this phase 2b study, 834 adults with BMI ≥25kg/m<sup>2</sup> and type 2 diabetes inadequately controlled with metformin (glycated hemoglobin A1c [HbA1c] of 7.0%─10.5% [53─91 mmol/mol]) were randomized to double-blind cotadutide 100µg (n=100), 200µg (n=256), or 300µg (n=256), placebo (n=110), or open-label liraglutide 1.8mg (n=110), all administered subcutaneously (NCT03235050). Coprimary endpoints were changes in HbA1c and body weight at week 14.<b> </b>The originally randomized interventions were continued to week 54.<b> </b>Liver damage biomarkers and liver fibrosis algorithms were assessed.</p> <p><b>Results</b>: Cotadutide significantly decreased HbA1c and body weight at weeks 14 and 54 versus placebo (all <i>P</i><0.001). Improvements in lipid profile, aspartate aminotransferase and alanine aminotransferase levels, <a>PRO-C3 level, fibrosis-4 index</a>, and <a>nonalcoholic fatty liver disease fibrosis score</a> were observed with cotadutide 300µg versus placebo, but not with liraglutide. Weight loss with cotadutide 200µg was similar to liraglutide 1.8mg, and greater with cotadutide 300µg versus liraglutide 1.8mg. <a>The most common adverse events with cotadutide (nausea, 35%; vomiting, 17%) decreased over time. </a></p> <p><b>Conclusions: </b>Cotadutide treatment for 54 weeks improved glycemic control and weight loss in participants with overweight/obesity and type 2 diabetes. Ad hoc analyses demonstrated improvements in hepatic parameters and support further evaluation of cotadutide in NASH. </p>

Adding Noninsulin Antidiabetic Drugs to Metformin Therapy for Type 2 Diabetes—Reply

JAMA ◽  
2010 ◽  
Vol 304 (4) ◽  
pp. 405
Author(s):  
Craig I. Coleman ◽  
Olivia J. Phung ◽  
Jennifer M. Scholle
Keyword(s):  
Type 2 Diabetes ◽  
Antidiabetic Drugs ◽  
Metformin Therapy
Sign in / Sign up

Export Citation Format

Share Document